Core Insights - Teva Pharmaceutical Industries Ltd. reported revenue of $4.18 billion for the quarter ended June 2025, reflecting a year-over-year increase of 0.3% but a revenue surprise of -2.47% compared to the Zacks Consensus Estimate of $4.28 billion [1] - The earnings per share (EPS) for the quarter was $0.66, surpassing the consensus estimate of $0.63, resulting in an EPS surprise of +4.76% [1] Financial Performance Metrics - Teva's stock has returned -0.6% over the past month, while the Zacks S&P 500 composite has increased by +3.4% [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3] Geographic Revenue Breakdown - Revenue from Europe was $1.3 billion, exceeding the average estimate of $1.25 billion, with a year-over-year change of +7% [4] - Revenue from International Markets was $495 million, below the average estimate of $602.4 million, representing a year-over-year decline of -16.5% [4] - Revenue from the United States was $2.15 billion, slightly below the estimated $2.19 billion, with a year-over-year increase of +1.9% [4] - Revenue from Anda in the United States was $365 million, surpassing the average estimate of $358.28 million, but showing a year-over-year decline of -2.1% [4] - Revenue from COPAXONE in Europe was $50 million, exceeding the average estimate of $40.5 million, with a year-over-year decline of -5.7% [4] - Revenue from respiratory products in Europe was $55 million, in line with the estimate of $55.07 million, reflecting a year-over-year decrease of -3.5% [4] - Revenue from generic products in International Markets was $410 million, below the average estimate of $478.57 million, with a year-over-year decline of -15.6% [4] - Revenue from COPAXONE in International Markets was $7 million, significantly below the estimate of $10.83 million, representing a year-over-year decline of -50% [4] - Revenue from AJOVY in the United States was $63 million, exceeding the average estimate of $50.8 million, with a year-over-year increase of +50% [4] - Total revenue from COPAXONE was $119 million, above the average estimate of $101.85 million, but showing a year-over-year decline of -19.6% [4] - Total revenue from other sources was $232 million, below the average estimate of $259.03 million, with a year-over-year increase of +118.9% [4] - API sales to third parties amounted to $135 million, below the average estimate of $156.49 million, with a year-over-year decline of -10.6% [4]

Core Viewpoint - Analysts project that Teva Pharmaceutical Industries Ltd. will report quarterly earnings of $0.63 per share, reflecting a 3.3% year-over-year increase, with revenues expected to reach $4.29 billion, a 3% increase from the same quarter last year [1]. Earnings Estimates - There has been a downward revision of 0.7% in the consensus EPS estimate over the last 30 days, indicating a collective reconsideration by analysts of their initial forecasts [2]. - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- COPAXONE- Total' at $101.85 million, a decrease of 31.2% from the prior-year quarter [5]. - 'Revenue- API sales to third parties' is expected to be $156.49 million, reflecting a 3.6% increase year-over-year [5]. - 'Revenue- Other- Total' is projected to reach $259.03 million, indicating a significant increase of 144.4% from the prior-year quarter [5]. Geographic Revenue Insights - 'Geographic Revenue- Europe' is estimated at $1.25 billion, showing a 3.3% increase from the year-ago quarter [6]. - 'Geographic Revenue- International Markets' is projected to be $602.40 million, reflecting a 1.6% increase year-over-year [6]. - 'Geographic Revenue- United States' is expected to reach $2.19 billion, indicating a 3.6% increase from the previous year [7]. Specific Product Revenue - 'Geographic Revenue- United States- Anda' is projected at $358.28 million, a decrease of 4% from the prior-year quarter [7]. - 'Geographic Revenue- Europe- COPAXONE' is expected to be $40.50 million, reflecting a decline of 23.6% year-over-year [7]. - 'Geographic Revenue- International Markets- Generic products' is estimated at $478.57 million, indicating a year-over-year change of -1.5% [8]. Additional Revenue Estimates - 'Geographic Revenue- International Markets- COPAXONE' is projected at $10.83 million, a decrease of 22.7% from the prior-year quarter [9]. - The consensus estimate for 'Geographic Revenue- United States- AJOVY' stands at $50.80 million, reflecting a 21% increase from the year-ago quarter [9]. Stock Performance - Teva's shares have shown a return of -1.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.9% [9].

Core Insights - Teva Pharmaceutical Industries Ltd. reported $3.89 billion in revenue for Q1 2025, a year-over-year increase of 1.9% and an EPS of $0.52, up from $0.48 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $3.97 billion by 1.92%, while the EPS exceeded the consensus estimate of $0.47 by 10.64% [1] Financial Performance - Teva's shares have returned +18.6% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The company currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Geographic Revenue Breakdown - United States: Revenue of $1.91 billion, exceeding the average estimate of $1.87 billion, with a year-over-year change of +10.7% [4] - Europe: AJOVY generated $58 million, slightly above the average estimate of $56.74 million, reflecting a +13.7% year-over-year change [4] - International Markets: COPAXONE revenue was $10 million, below the estimate of $10.67 million, representing a -16.7% change year-over-year [4] - Generic products in International Markets generated $468 million, slightly below the estimate of $487.47 million, with a -1.9% year-over-year change [4] - Europe: COPAXONE revenue was $42 million, below the estimate of $43.68 million, indicating a -26.3% year-over-year change [4] - Europe: Generic products revenue was $989 million, slightly below the estimate of $991.61 million, with a -1.5% year-over-year change [4] - Europe: Other products generated $50 million, significantly below the estimate of $95.70 million, reflecting a -46.8% year-over-year change [4] - Europe: Respiratory products revenue was $55 million, below the estimate of $60.84 million, indicating a -16.7% year-over-year change [4] - International Markets: Other products generated $61 million, below the estimate of $94.61 million, representing a -33% year-over-year change [4] - Total revenue from COPAXONE was $106 million, exceeding the estimate of $84.97 million, with a +7.1% year-over-year change [4] - API sales to third parties amounted to $130 million, surpassing the estimate of $115.17 million, reflecting a +1.6% year-over-year change [4]

Core Insights - Teva Pharmaceutical Industries Ltd. reported Q1 2025 revenues of $3.9 billion, marking a 5% increase in local currency terms compared to Q1 2024, driven by strong performance in innovative products and generics [4][5][7] - The company is on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth Strategy, with a revised full-year 2025 revenue outlook of $16.8 to $17.2 billion [4][5][71] - Teva's innovative products, including AUSTEDO, AJOVY, and UZEDY, collectively generated revenues of $589 million, each growing over 25% year-over-year [5][8] Financial Performance - Q1 2025 net income attributable to Teva was $214 million, with diluted earnings per share of $0.18, compared to a net loss of $139 million and a loss per share of $0.12 in Q1 2024 [17] - Non-GAAP diluted EPS for Q1 2025 was $0.52, an increase of 8% year-over-year [4][17] - Adjusted EBITDA for Q1 2025 was $1.041 billion, a 4% increase from $1.005 billion in Q1 2024 [18] Segment Performance - In the United States segment, revenues increased by 11% to $1.91 billion, driven by higher sales of innovative products and generics [25][26] - The Europe segment saw a 6% decrease in revenues to $1.194 billion, primarily due to lower revenues from COPAXONE and mature innovative product rights [42][43] - The International Markets segment reported revenues of $582 million, a 2% decrease, impacted by regulatory price reductions and competition in Japan [54][56] Product Highlights - AUSTEDO revenues in Q1 2025 were $396 million, a 40% increase year-over-year, attributed to volume growth and the launch of AUSTEDO XR [32][33] - AJOVY revenues increased by 18% to $53 million, driven by volume growth and an increase in market share [31][47] - UZEDY revenues surged by 156% to $39 million, reflecting strong demand following its launch [35] Strategic Initiatives - Teva is focused on transforming into a modern biopharmaceutical company, targeting approximately $700 million in net savings by 2027 [4][5][8] - The company is actively pursuing the divestiture of its API business to streamline operations and enhance capital allocation [68][69] - Teva plans to host an Innovation & Strategy Day on May 29, 2025, to discuss its growth strategy and future initiatives [4][73]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.47 per share, a decline of 2.1% year-over-year, with revenues projected at $3.97 billion, reflecting a 3.9% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 1.6% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenue- COPAXONE- Total' to be $84.97 million, down 14.2% from the year-ago quarter [5]. - 'Revenue- API sales to third parties' is projected at $115.17 million, indicating a decrease of 10% year-over-year [5]. - 'Revenue- Other- Total' is estimated at $221.49 million, reflecting a significant decline of 30.4% from the previous year [5]. Geographic Revenue Insights - 'Geographic Revenue- International Markets' is expected to reach $615.76 million, a year-over-year increase of 3.1% [6]. - 'Geographic Revenue- United States' is projected at $1.87 billion, showing an 8.5% increase compared to the prior year [6]. - 'Geographic Revenue- United States- COPAXONE' is estimated at $32.38 million, up 7.9% from the year-ago quarter [6]. - 'Geographic Revenue- United States- BENDEKA / TREANDA' is forecasted to be $35.39 million, down 23.1% year-over-year [7]. - 'Geographic Revenue- United States- AUSTEDO' is expected to reach $360.74 million, reflecting a 27.9% increase from the previous year [7]. - 'Geographic Revenue- United States- Anda' is projected at $370.89 million, indicating a decrease of 2.7% year-over-year [8]. - 'Geographic Revenue- Europe- COPAXONE' is expected to be $43.68 million, down 23.4% from the year-ago quarter [8]. - 'Geographic Revenue- Europe- Respiratory products' is projected at $60.84 million, reflecting a decline of 7.8% year-over-year [9]. - 'Geographic Revenue- International Markets- Generic products' is expected to reach $487.47 million, indicating a 2.2% increase from the prior year [9]. Stock Performance - Over the past month, Teva shares have increased by 17.3%, outperforming the S&P 500 composite's 0.4% change [10]. - Teva holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [10].